---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-103975"
form_type: "8-K"
ticker: "ELDN"
cik: "0001404281"
company_name: "Eledon Pharmaceuticals, Inc."
filed_at: "2025-08-06T23:59:59+00:00"
generated_at: "2026-05-17T19:03:38.573000+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Eledon reports updated Phase 1b data for tegoprubart; eGFR ~68 at 12 months, predicted 5-year graft survival >96%

## Summary
- On-treatment patients (n=12) showed mean eGFR ~68 mL/min/1.73m² at 12 months; ITT population (n=15) ~63 mL/min/1.73m².
- Preliminary abbreviated iBox score -4.11 (on-treatment) vs -2.98 historical CNI; predicts 5-year graft survival >96%.
- No deaths, graft loss, drug-related tremor, or new-onset diabetes; six rejection episodes (18.8%), all successfully treated.
- Patients who remained on tegoprubart after rejection had mean eGFR ~73 mL/min/1.73m² at 12 months; switched to tacrolimus had ~34.
- Topline results from Phase 2 BESTOW trial comparing tegoprubart to tacrolimus expected in November 2025.

## SEC filing metadata
- accession: 0000950170-25-103975
- form_type: 8-K
- ticker: ELDN
- cik: 0001404281
- company_name: Eledon Pharmaceuticals, Inc.
- filed_at: 2025-08-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/0000950170-25-103975-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1404281/000095017025103975/eldn-20250806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-103975
- JSON: https://secwatch.observer/filing/0000950170-25-103975.json
- Plain text: https://secwatch.observer/filing/0000950170-25-103975.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.